ACLX Stock Summary and Trading Ideas (Arcellx | NASDAQ:ACLX)

Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.

Arcellx trades on the NASDAQ stock market under the symbol ACLX.

As of February 13, 2026, ACLX stock price declined to $68.50 with 658,729 million shares trading.

ACLX has a beta of 0.38, meaning it tends to be less sensitive to market movements. ACLX has a correlation of 0.02 to the broad based SPY ETF.

ACLX has a market cap of $3.96 billion. This is considered a Mid Cap stock.

Last quarter Arcellx reported $5 million in Revenue and -$.99 earnings per share. This fell short of revenue expectation by $-7 million and exceeded earnings estimates by $.01.

In the last 3 years, ACLX traded as high as $107.37 and as low as $26.32.

The top ETF exchange traded funds that ACLX belongs to (by Net Assets): VTI, XBI, IWM, VB, VXF.

ACLX has underperformed the market in the last year with a return of +7.5%, while the SPY ETF gained +13.0%. In the last 3 month period, ACLX fell short of the market, returning -21.6%, while SPY returned +1.7%. However, in the most recent 2 weeks ACLX has outperformed the stock market by returning +0.3%, while SPY returned -1.5%.

ACLX support price is $66.47 and resistance is $70.83 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ACLX shares will trade within this expected range on the day.